Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | TTBK1 | Q5TCY1 | 4/20 | 0.42 |
| ▸ | TTBK2 | Q6IQ55 | 4/20 | 0.42 |
| ▸ | KDR | P35968 | 3/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17528585 | 0.84 | ADRA2A (0.53) | SYKTTBK1TTBK2KDREGFR | |
| SCHEMBL17528582 | 0.81 | TTBK1 (0.64) | TTBK1TTBK2KDREGFRPDGFRB | |
| SCHEMBL19033044 | 0.75 | KDR (0.44) | KDREGFRPDGFRBADRA2AADRA2C | |
| SCHEMBL19033751 | 0.74 | CRHR1 (0.39) | KDREGFRPDGFRBBTK | |
| SCHEMBL12736495 | 0.71 | SYK (0.42) | SYKTTBK1TTBK2KDREGFR | |
| SCHEMBL18540801 | 0.70 | TTK (0.47) | SYKKDREGFRPDGFRBMAP4K1 | |
| SCHEMBL27393525 | 0.70 | DYRK1A (0.44) | TTBK1TTBK2MKNK1MKNK2 | |
| SCHEMBL17528583 | 0.69 | KDR (0.48) | KDREGFRPDGFRBADRA2AADRA2C | |
| SCHEMBL27392791 | 0.67 | JAK2 (0.44) | SYKKDREGFRPDGFRBTGFBR1 | |
| SCHEMBL17528557 | 0.66 | BRD4 (0.37) | KDREGFRPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11111252-B2 | Pyrimidine compounds and pyrimido indole compounds and methods of use | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2021-09-07 | — | — | US | disclosed |
| US-20200369681-A1 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2020-11-26 | — | — | US | disclosed |
| US-20170253612-A1 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2017-09-07 | — | — | US | disclosed |
| US-9688690-B2 | Pyrimidine compounds and pyrimido indole compounds and methods of use | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2017-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369681-A1 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | DPYD, TYMP, TPMT | SYK 821/4885TTBK1 1071/4885TTBK2 950/4885 |
| US-20170253612-A1 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | DPYD, HPRT1, TPMT | SYK 738/4885TTBK1 2498/4885TTBK2 2277/4885 |
| US-11111252-B2 | Pyrimidine compounds and pyrimido indole compounds and methods of use | DPYD, TYMP, TPMT | SYK 821/4885TTBK1 1071/4885TTBK2 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.